Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The 0.3% pancreatitis rate in trials, while low, represents a real concern for those with prior episodes
From Will it actually work for me
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
(2023) published in The Lancet evaluated retatrutide dosing in subjects with type 2 diabetes
A New Oral Option for Diabetes and Obesity HS-10270 is a novel oral formulation of a GLP-1 receptor agonist designed to help manage blood sugar levels and promote weight losstwo key therapeutic goals for patients with type 2 diabetes and obesity
US$ 24.43
US$ 20.78
US$ 26.69
US$ 21.60
US$ 22.46
US$ 25.90
